The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections

BACKGROUND: Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible Gram-positive (GP) pathogens. METHODS: Data collected from a retrospective o...

Descripción completa

Detalles Bibliográficos
Autores principales: Redell, Mark, Sierra-Hoffman, Miguel, Assi, Maha, Bochan, Markian, Chansolme, David, Gandhi, Anurag, Sheridan, Kathleen, Soosaipillai, Ivan, Walsh, Thomas, Massey, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903788/
https://www.ncbi.nlm.nih.gov/pubmed/31844635
http://dx.doi.org/10.1093/ofid/ofz479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903788/
https://www.ncbi.nlm.nih.gov/pubmed/31844635
http://dx.doi.org/10.1093/ofid/ofz479

Ejemplares similares